Enhanced expression of neurotrophic factors in the injured spinal cord through vaccination with myelin basic protein-derived peptide pulsed dendritic cells.
Vaccination of spinal cord injury (SCI) mice with myelin basic protein-derived peptide (A91) pulsed dendritic cells (DC) to enhance brain-derived neurotrophic factor and neurotrophin-3 (NT-3) expression in injured spinal cord. To investigate the effect of A91-pulsed DC (A91-DC) on expression of neurotrophic factor in injured spinal cord. SCI leads to progressive secondary tissue degeneration, and no satisfactory treatment is currently available. Accumulating evidence indicates that administration of neurotrophic factors to injured spinal cord is partially successful at promoting nerve tissue repair. However, most of strategy can cause secondary injury and limiting their wide clinical application. Proliferation of T cells and the capability of CD4 T cells to secret neurotrophic factors were first measured in vitro to demonstrate the stimulus action of the A91-DC. In SCI mice model, enzyme-linked immunosorbent assay and immunofluorescence was employed to investigate the brain-derived neurotrophic factor and NT-3 expression in injured spinal cord. Furthermore, the neuroprotective effect of A91-DC in injured spinal cord was examined through histology measurement. In this study, we demonstrated that A91-DC promoted the capability of T cells to secret neurotrophic factors and in the subacute phase of SCI. Moreover, vaccination with A91-DC enhanced the expression level of brain-derived neurotrophic factor and NT-3 and exerted neuroprotective effect in injured spinal cord. The findings of study demonstrate that the therapeutic strategy of vaccination A91-DC is a potential minimally invasive approach that could provide strong neurotrophic factor support after SCI.